ANGO:NSD-AngioDynamics, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 14.36

Change

-0.02 (-0.14)%

Market Cap

USD 0.55B

Volume

0.17M

Average Target Price

USD 18.00 (+25.35%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-27 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical, Inc

+3.45 (+0.47%)

USD85.39B 82.75 64.91
HOLX Hologic, Inc

+1.28 (+1.88%)

USD17.54B 16.21 13.60
MASI Masimo Corporation

+9.00 (+3.67%)

USD13.51B 63.74 44.12
NVCR NovoCure Limited

+10.16 (+8.71%)

USD11.88B 696.63 396.62
XRAY DENTSPLY SIRONA Inc

+0.34 (+0.66%)

USD11.22B 126.19 38.49
RGEN Repligen Corporation

+5.56 (+3.06%)

USD9.55B 219.92 114.54
IRTC iRhythm Technologies, Inc

+10.50 (+4.70%)

USD6.45B N/A N/A
ICUI ICU Medical, Inc

+1.86 (+1.01%)

USD3.88B 48.92 19.60
STAA STAAR Surgical Company

+3.21 (+4.59%)

USD3.22B 432.79 450.33
MMSI Merit Medical Systems, Inc

-0.12 (-0.22%)

USD3.05B 379.20 38.78

ETFs Containing ANGO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.31% 32% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.31% 32% F 34% F
Trailing 12 Months  
Capital Gain -6.57% 29% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.57% 29% F 35% F
Trailing 5 Years  
Capital Gain 22.01% 31% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.01% 31% F 47% F
Average Annual (5 Year Horizon)  
Capital Gain 3.81% N/A N/A 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.81% N/A N/A 45% F
Risk Return Profile  
Volatility (Standard Deviation) 31.60% N/A N/A 45% F
Risk Adjusted Return 12.05% N/A N/A 40% F
Market Capitalization 0.55B 48% F 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.10 91% A- 81% B-
Price/Book Ratio 1.05 97% A+ 76% C
Price / Cash Flow Ratio -37.50 87% B+ 91% A-
EV/EBITDA 32.23 59% F 25% F
Management Effectiveness  
Return on Equity -31.76% 29% F 29% F
Return on Invested Capital -26.70% 32% F 26% F
Return on Assets -1.84% 35% F 39% F
Debt to Equity Ratio 8.79% 92% A- 77% C+
Technical Ratios  
Short Ratio 5.83 29% F 27% F
Short Percent 4.67% 48% F 40% F
Beta 0.60 84% B 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector